Unknown

Dataset Information

0

Discontinuation of Long-acting Injectable Cabotegravir-Rilpivirine in a Large Clinic Cohort.

ABSTRACT: Little is known about long-acting injectable cabotegravir-rilpivirine discontinuation outside clinical trials. In a large clinic cohort, 1 in 6 people with HIV discontinued long-acting injectable cabotegravir-rilpivirine over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for people with HIV with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation.

SUBMITTER: Christopoulos KA 

PROVIDER: S-EPMC12534727 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Discontinuation of Long-acting Injectable Cabotegravir-Rilpivirine in a Large Clinic Cohort.

Christopoulos Katerina A KA   Erguera Xavier X   Grochowski Janet J   Hickey Matthew M   Imbert Elizabeth E   Dilworth Samantha S   Appa Ayesha A   Cox Chesa C   Shiels Mary M   Oskarsson Jon J   Gandhi Monica M  

Open forum infectious diseases 20250926 10

Little is known about long-acting injectable cabotegravir-rilpivirine discontinuation outside clinical trials. In a large clinic cohort, 1 in 6 people with HIV discontinued long-acting injectable cabotegravir-rilpivirine over a median of ∼18 months. Injection-related pain was common. Virologic failure and efficacy concerns drove discontinuation for people with HIV with adherence challenges. Most had viral suppression on alternate antiretrovirals post-discontinuation. ...[more]

Similar Datasets

Unknown Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic.
| S-EPMC11893977 | biostudies-literature
Unknown Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV.
| S-EPMC11650856 | biostudies-literature
Unknown Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.
| S-EPMC11259215 | biostudies-literature
Unknown Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.
| S-EPMC9487705 | biostudies-literature
Unknown Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.
| S-EPMC12313467 | biostudies-literature
Unknown Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
| S-EPMC7021098 | biostudies-literature
Unknown The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
| S-EPMC8050198 | biostudies-literature
Unknown Long-acting injectable cabotegravir for the prevention of HIV infection.
| S-EPMC7382946 | biostudies-literature
Unknown Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
| S-EPMC12087306 | biostudies-literature
Unknown Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
| S-EPMC11367594 | biostudies-literature